Los Angeles Capital Management LLC Acquires 40,383 Shares of Alumis Inc. $ALMS

Los Angeles Capital Management LLC increased its holdings in Alumis Inc. (NASDAQ:ALMS) by 32.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 163,084 shares of the company’s stock after purchasing an additional 40,383 shares during the period. Los Angeles Capital Management LLC owned approximately 0.16% of Alumis worth $1,592,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Alumis by 64.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after purchasing an additional 4,926 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Alumis by 24.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after buying an additional 11,949 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Alumis during the 1st quarter worth approximately $111,000. Rhumbline Advisers lifted its position in shares of Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after buying an additional 2,949 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Alumis by 163.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock valued at $3,504,000 after buying an additional 724,133 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wells Fargo & Company upped their price target on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Stifel Nicolaus began coverage on shares of Alumis in a report on Wednesday, February 25th. They issued a “buy” rating and a $44.00 target price on the stock. HC Wainwright cut shares of Alumis from a “buy” rating to a “neutral” rating and set a $25.00 target price for the company. in a research report on Friday, May 15th. Finally, Raymond James Financial began coverage on shares of Alumis in a report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alumis presently has an average rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Performance

Shares of ALMS opened at $20.06 on Thursday. The stock has a fifty day moving average price of $22.84 and a two-hundred day moving average price of $21.07. Alumis Inc. has a 52-week low of $2.76 and a 52-week high of $30.60. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -10.13 and a beta of -0.56.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. As a group, research analysts predict that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.